Yes, epigenetic changes hold great promise as biomarkers for cancer diagnosis, prognosis, and treatment response. For instance, the methylation status of certain genes can help in the early detection of cancers or in predicting the course of the disease. MGMT promoter methylation status is used to predict the response to alkylating agents in glioblastoma treatment.